Search results
Heads Up: Abbvie's Migraine Portfolio 'Very, Very Strong'
MediaPost· 4 days agoIn the wake of Abbvie’s loss of exclusivity for its blockbuster Humira anti-inflammatory drug, its migraine-fighting meds -- Ubrelva, Qulipta and Botox -- have emerged as ...
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
The Marysville Advocate· 2 days agoThis offer is conditioned on, among other things, the closing price per share of AbbVie's common stock exceeding the Offer Price on the last full trading day prior to the ...
The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value
GuruFocus.com via Yahoo Finance· 6 days agoIn this article, we will take a look into AbbVie Inc's (NYSE:ABBV) DCF analysis, a reliable and...
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory...
The Port Lavaca Wave· 4 days ago- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD)
Amneal’s IPX-203 shows promising results for motor fluctuations in Parkinson’s disease
Clinical Trials Arena via Yahoo Finance· 59 minutes agoFurthermore, there are two novel levodopa delivery systems in Phase III development for PD that are...
AbbVie inks deal potentially worth $1.7 billion for new IBD drug
Crain s Chicago Business· 4 days agoAbbVie's latest move in inflammatory bowel disease treatments is a licensing agreement to develop a next generation antibody engineered by Beijing-based FutureGen. The terms ...
Sei Investments Co. Buys 25,042 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 7 days agoSei Investments Co. raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned ...
AbbVie inks immune disorder drug licensing deal with China's FutureGen
AOL· 4 days agoAbbVie has been counting on its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira following the entry of biosimilars in the ...
AbbVie joins TL1A race via $150M upfront deal with China's FutureGen
FierceBiotech· 4 days agoAbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel ...
AbbVie Signs On To Recruit Diverse Talent at Upcoming HBCU Connect Annual Conference & Career Fair...
BlackNews.com· 3 days agoOn Friday, June 28th, 2024 at Washington Nationals Stadium in Washington, DC, HBCU CONNECT will host...